人群层面HbA1c筛查对减少中年成人糖尿病诊断延迟的影响:一项英国生物银行分析
基于英国生物银行40-70岁参与者数据,分析入组时HbA1c测量(未反馈)与后续临床诊断的时间。在无糖尿病诊断的166,846人中,1.0%基于入组HbA1c水平存在未诊断糖尿病,中位诊断延迟2.2年。结论认为HbA1c筛查可较常规临床诊疗将糖尿病诊断时间中位缩短2.2年。
要点
- 在无糖尿病诊断的参与者中,1.0%(1703/166,846)基于入组HbA1c水平存在未诊断糖尿病。
- 未诊断糖尿病患者从入组HbA1c测量到临床诊断的中位时间为2.2年。
- 女性、入组时较低HbA1c和BMI的参与者临床诊断延迟最长。
核心结论
- 基于人群的研究表明,对40-70岁成人进行HbA1c筛查较常规临床诊疗可将糖尿病诊断时间中位缩短2.2年。
- 研究结果支持使用HbA1c筛查以减少个体处于未诊断糖尿病状态的时间。
研究设计与样本
- 研究基于英国生物银行人群,纳入40-70岁、入组时测量HbA1c(未反馈给参与者/临床医生)并链接初级和二级医疗数据的参与者(n=179,923)。
- 识别出已有糖尿病诊断者13,077例(7.3%),其余无糖尿病诊断者166,846例中,以入组HbA1c≥48 mmol/mol(≥6.5%)识别未诊断糖尿病。
- 采用Kaplan-Meier分析评估从入组HbA1c测量到后续临床糖尿病诊断的时间(最长10年),采用Cox回归识别与诊断延迟相关的临床因素。
主要发现
- 在无糖尿病诊断的参与者中,1.0%(1703/166,846)基于校准的入组HbA1c水平存在未诊断糖尿病,中位HbA1c为51.3 mmol/mol(IQR 49.1-57.2)(6.8% [6.6-7.4])。
- 这些参与者相对于13,077例已有糖尿病诊断者,占研究人群糖尿病病例的额外13.0%。
- 未诊断糖尿病患者从入组到临床诊断的中位时间为2.2年,临床诊断时中位HbA1c为58.2 mmol/mol(IQR 51.0-80.0)(7.5% [6.8-9.5])。
- 女性、入组时HbA1c和BMI较低的参与者临床诊断延迟最长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Screening programmes can detect cases of undiagnosed diabetes earlier than symptomatic or incidental diagnosis. However, the improvement in time to diagnosis achieved by screening programmes compared with routine clinical care is unclear. We aimed to use the UK Biobank population-based study to provide the first population-based estimate of the reduction in time to diabetes diagnosis that could be achieved by HbA1c-based screening in middle-aged adults. METHODS: We studied UK Biobank participants aged 40-70 years with HbA1c measured at enrolment (but not fed back to participants/clinicians) and linked primary and secondary healthcare data (n=179,923) and identified those with a pre-existing diabetes diagnosis (n=13,077, 7.3%). Among the remaining participants (n=166,846) without a diabetes diagnosis, we used an elevated enrolment HbA1c level (≥48 mmol/mol [≥6.5%]) to identify those with undiagnosed diabetes. For this group, we used Kaplan-Meier analysis to assess the time between enrolment HbA1c measurement and subsequent clinical diabetes diagnosis up to 10 years, and Cox regression to identify clinical factors associated with delayed diabetes diagnosis. RESULTS: In total, 1.0% (1703/166,846) of participants without a diabetes diagnosis had undiagnosed diabetes based on calibrated HbA1c levels at UK Biobank enrolment, with a median HbA1c level of 51.3 mmol/mol (IQR 49.1-57.2) (6.8% [6.6-7.4]). These participants represented an additional 13.0% of diabetes cases in the study population relative to the 13,077 participants with a diabetes diagnosis. The median time to clinical diagnosis for those with undiagnosed diabetes was 2.2 years, with a median HbA1c at clinical diagnosis of 58.2 mmol/mol (IQR 51.0-80.0) (7.5% [6.8-9.5]). Female participants with lower HbA1c and BMI measurements at enrolment experienced the longest delay to clinical diagnosis. CONCLUSIONS/INTERPRETATION: Our population-based study shows that HbA1c screening in adults aged 40-70 years can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care. The findings support the use of HbA1c screening to reduce the time for which individuals are living with undiagnosed diabetes.
引用
- Young KG, McGovern AP, Barroso I, et al. The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia. 2022. PMID: 36411396. doi:10.1007/s00125-022-05824-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。